Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | TGM2 | P21980 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.61 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.61 |
| ▸ | CPB1 | P15086 | 1/20 | 0.58 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.58 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.55 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.54 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.53 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.53 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.53 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.53 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.53 |
| ▸ | ANPEP | P15144 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL235394 | 1.00 | HTT (0.68) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL2076614 | 1.00 | HTT (0.68) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL7863455 | 1.00 | HTT (0.68) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL29040497 | 1.00 | HTT (0.68) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL29040501 | 1.00 | HTT (0.68) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL19240717 | 1.00 | HTT (0.68) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL3049211 | 1.00 | HTT (0.68) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| Hydrochloric Acid SCHEMBL5279548 | 0.98 | HTT (0.67) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| Hydrochloric Acid SCHEMBL6375520 | 0.98 | HTT (0.67) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL335088 | 0.98 | HTT (0.70) | HTTTGM2LMNASMN1; SMN2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208984-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | VIRGINIA COMMONWEALTH UNIVERSITY | 2024-06-27 | — | — | US | disclosed |
| EP-4313051-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | Virginia Commonwealth University (US) | 2024-02-07 | — | — | EP | disclosed |
| US-11833208-B2 | PLK1 selective degradation inducing compound | UPPTHERA, INC. (KR) | 2023-12-05 | — | — | US | disclosed |
| US-20230372498-A1 | PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND | UPPTHERA (KR) | 2023-11-23 | — | — | US | disclosed |
| US-20230104076-A1 | PLK1 Selective Degradation Inducing Compound | UPPTHERA INC. (KR) | 2023-04-06 | — | — | US | disclosed |
| WO-2022212471-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2022-10-06 | — | — | WO | disclosed |
| CN-113784969-A | PLK1 Selective degradation inducing Compounds | 厄普特拉公司 | 2021-12-10 | — | — | CN | disclosed |
| US-9107954-B2 | Bivalent ligands for the treatment of neurological disorders | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2015-08-18 | — | — | US | disclosed |
| US-20150157730-A1 | Bivalent Ligands for the Treatment of Neurological Disorders | VIRGINIA COMMONWEALTH UNIVERSITY | 2015-06-11 | — | — | US | disclosed |
| US-8946254-B2 | Bivalent ligands for the treatment of neurological disorders | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140357656-A1 | Bivalent Ligands for the Treatment of Neurological Disorders | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2014-12-04 | — | — | US | disclosed |
| WO-2013106528-A1 | BIVALENT LIGANDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2013-07-18 | — | — | WO | disclosed |
| US-7589219-B2 | 2,5-bis-diamine-[1,4]benzoquinonic derivatives, useful for the treatment of alzheimer's disease, method for preparing them and intermediates of said method | ALMA MATER STUDIORUM-UNIVERSITA' DI BOLOGNA (IT) | 2009-09-15 | — | — | US | disclosed |
| US-20050261345-A1 | 2,5-Bis-diamine-'1,4! benzoquinone derivatives, for the treatment of alzheimer's disease a process for their preparation and intermediates therefor | ALMA MATER STUDIORUM-UNIVERSITA' DI BOLOGNA (IT) | 2005-11-24 | — | — | US | disclosed |
| EP-1497257-A1 | 2,5-BIS-DIAMINE-[1,4] BENZOQUINONE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE, A PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREFOR | Alma Mater Studiorum -Universita' di Bologna (IT) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003087035-A1 | 2,5-BIS-DIAMINE-'1,4! BENZOQUINONE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE A PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREFOR | ALMA MATER STUDIORUM-UNIVERSITA' DI BOLOGNA (IT) | 2003-10-23 | — | — | WO | disclosed |
| EP-0613483-A1 | NEW LUPANE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Aventis Pharma S.A. (FR) | 1994-09-07 | — | — | EP | disclosed |
| WO-1993010142-A1 | NEW LUPANE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | RHONE-POULENC RORER S.A. (FR) | 1993-05-27 | — | — | WO | disclosed |
| EP-0542622-A1 | New lupane derivatives, a process for their production and pharmaceutical compositions containing them | Aventis Pharma S.A. (FR) | 1993-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261345-A1 | 2,5-Bis-diamine-'1,4! benzoquinone derivatives, for the treatment of alzheimer's disease a process for their preparation and intermediates therefor | PSEN2, BACE2, WEE2 | HTT 714/4885TGM2 532/4885LMNA 1560/4885 |
| US-20150157730-A1 | Bivalent Ligands for the Treatment of Neurological Disorders | CCR5, OPRM1, OPRK1 | HTT 1300/4885TGM2 2826/4885LMNA 4714/4885 |
| US-20230372498-A1 | PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | HTT 2333/4885TGM2 2294/4885LMNA 2055/4885 |
| US-20230104076-A1 | PLK1 Selective Degradation Inducing Compound | PLK1, BUB1B, BUB1 | HTT 2333/4885TGM2 2294/4885LMNA 2055/4885 |
| US-20140357656-A1 | Bivalent Ligands for the Treatment of Neurological Disorders | CCR5, OPRM1, OPRK1 | HTT 1300/4885TGM2 2826/4885LMNA 4714/4885 |
| US-20240208984-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | OPRM1, OPRK1, CCR5 | HTT 1569/4885TGM2 2998/4885LMNA 4122/4885 |
| US-11833208-B2 | PLK1 selective degradation inducing compound | PLK1, BUB1B, BUB1 | HTT 2333/4885TGM2 2294/4885LMNA 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.